Nexavar
Nexavar Official FDA information, side effects and uses.
Decision is too late for cancer sufferer - The Northern Echo
Posted by Nexavar (Nexavar) on Sun, 29 Jul 2007 00:15:39 +0000
Bayer and Onyx submit supplemental NDA for Nexavar - News-Medical.net
Bayer and Onyx Submit Supplemental New Drug Application for ... - MedIndia
Clavis Pharma Announces Initiation of Malignant Melanoma Phase II ... - PharmaLive.com (press release)
Clavis Pharma announces initiation of - Ad-Hoc-News (Pressemitteilung)
Posted by Nexavar (Nexavar) on Sun, 29 Jul 2007 00:15:39 +0000
| Decision is too late for cancer sufferer The Northern Echo, UK - Ironically, Mrs Devonport's consultant decided to put her on Nexavar, a similar drug to Sutent which is also licensed but can only be purchased privately. ... Kidney cancer drug decision hailed as 'major breakthrough' |
Bayer and Onyx submit supplemental NDA for Nexavar - News-Medical.net
| Bayer and Onyx submit supplemental NDA for Nexavar News-Medical.net, Australia - Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has ... |
Bayer and Onyx Submit Supplemental New Drug Application for ... - MedIndia
| Bayer and Onyx Submit Supplemental New Drug Application for ... MedIndia, India - Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer. The companies also confirmed that they are planning a ... |
Clavis Pharma Announces Initiation of Malignant Melanoma Phase II ... - PharmaLive.com (press release)
| Clavis Pharma Announces Initiation of Malignant Melanoma Phase II ... PharmaLive.com (press release), PA - Its goal is to document ELACYT's efficacy in combination therapy with Nexavar in patients who have relapsed after treatment with other medications. ... |
Clavis Pharma announces initiation of - Ad-Hoc-News (Pressemitteilung)
| Clavis Pharma announces initiation of Ad-Hoc-News (Pressemitteilung), Germany - Clavis Pharma announces initiation of malignant melanoma phase II clinical study of ELACYT in combination with Nexavar and provides update on the Melanoma ... |
